Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
about
New developments in the management of moderate-to-severe hemophilia BEmerging and future therapies for hemophiliaLong-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.Aspects of prophylactic treatment of hemophiliaLong-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.Industrial production of clotting factors: Challenges of expression, and choice of host cells.Longer-acting clotting factor concentrates for hemophilia.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.New products for the treatment of haemophilia.Current and future prospects for hemophilia gene therapy.Haemophilia treatment in 2030.The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.Emerging drugs for the treatment of hemophilia A and B.2017 Clinical trials update: Innovations in hemophilia therapy.Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.Extended half-life clotting factor concentrates: results from published clinical trials.Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.A new era for hemophilia B treatment.Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.Evaluation of Nonacog Beta Pegol Long-term Safety in the Immune-deficient Rowett Nude Rat (Crl:NIH-Foxn1rnu).The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX.Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity.Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.Weekly recombinant FIX prophylaxis for severe haemophilia B in normal clinical practice: data from UKHCDO and Finland.A new modeling approach allowing prediction and comparison of the long-term outcomes of treatments for hemophilia B.Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol.Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.Nonacog Beta Pegol: A Review in Haemophilia B.Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays.Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.Extended Half-Life Factor VIII and Factor IX Preparations.Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua.
P2860
Q26751323-88411776-6D1F-4CF5-BE1D-50748056A038Q26781143-F532ECA8-F7E4-4CC2-AC0C-548E0E3003CAQ27342796-CBE745F5-4ABC-4DD4-BE1D-D452D8FFED4EQ28078562-7CBF2F10-1755-443A-B341-6A3EF7AA9E90Q36780134-1D0FE916-5EE8-4EAD-A657-FB55EE5BAAF3Q38371071-1D7A791A-372F-4065-B52E-C907C8DAF4BBQ38534584-23D09C48-1DD0-494C-928A-44085E0B391FQ38543283-DB32611E-9152-4407-AC9E-EDFC6557DCB5Q38574414-E9CFD605-97EF-49A3-B830-E1C12B080945Q38604626-1604AB4C-3F10-4132-9084-1B8C3751C452Q38827606-FF0A3ECB-1042-4D24-97CE-8A42E9C342CAQ38842671-9CADFFD3-96A9-4295-B275-3A2CF3C0614DQ38867485-F6A05AEA-CF9D-45D9-B42B-CF95DDF96F10Q38933707-35234D61-38B4-47EE-99B5-01BF875DE9BCQ38937725-E3A7929C-004E-4398-8A75-ADBB3A277BE7Q38944641-4D6C6141-BCDB-4FA5-97A4-07AB400032E2Q39204747-50F83D88-340F-46B8-8B9B-BE6604EC522DQ39609294-DB38CFC3-4830-49A4-AB8F-BE2F6C38CCFDQ39952685-C1416A9B-2D22-47B5-9FED-6C7D2E37FDADQ39979927-11E5C1F5-48D9-4E6C-9C78-65CD3644668DQ40573329-3906744E-7A51-4EF4-8FC4-9AAE45C2EDA5Q40768285-0682D4B8-40B3-481C-A8F8-76B501D4D131Q44576554-8B7D4799-8110-4F08-B84D-B6FFF6F06613Q44871479-71CF5C61-A0C3-42DF-8327-A7E4CE9C1F78Q45855670-6E903A42-B41F-42CE-816F-0EC71EF85013Q45856976-0B0381D7-6DF3-4FC9-B268-0768EC49A007Q45857503-F4AAEBFD-9E3C-4649-9FA9-22BD88FF6FB8Q45863279-C9E94CAA-4993-45A3-890D-DCE96F27F3E8Q45867846-CDDEDA66-D3F2-4983-ACF7-56ECC04FBC7AQ45868343-D4A82B5F-4F09-4F6C-AF73-3C51D03FEF7AQ45870406-8E8984DA-359D-4C62-B337-E541BF53F438Q45872102-42F898DC-EA36-415A-9973-C9B5B9C8016AQ45874183-ED403B55-C90A-4241-BBD0-A81208949937Q45874270-F2A774B7-0521-4104-8B08-6BACCCC2C447Q45875490-5769B010-2061-43B7-8D4A-98480616677BQ45885298-028506B0-F948-4D03-9336-1448A91940CDQ45885955-B5E0FD5C-8E13-48B5-85FE-7E750F7B4AECQ55025596-65469DDC-50E5-4064-BF4C-2CEE385C60C1Q55313906-2F3940DE-CA22-4557-AA34-23295B1C7B6DQ55617834-01F179C8-CE8B-449A-AA09-F6D2C3BF8D74
P2860
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Recombinant long-acting glycoP ...... ional randomized phase 3 trial
@ast
Recombinant long-acting glycoP ...... ional randomized phase 3 trial
@en
Recombinant long-acting glycoP ...... ional randomized phase 3 trial
@nl
type
label
Recombinant long-acting glycoP ...... ional randomized phase 3 trial
@ast
Recombinant long-acting glycoP ...... ional randomized phase 3 trial
@en
Recombinant long-acting glycoP ...... ional randomized phase 3 trial
@nl
prefLabel
Recombinant long-acting glycoP ...... ional randomized phase 3 trial
@ast
Recombinant long-acting glycoP ...... ional randomized phase 3 trial
@en
Recombinant long-acting glycoP ...... ional randomized phase 3 trial
@nl
P2093
P2860
P921
P1433
P1476
Recombinant long-acting glycoP ...... ional randomized phase 3 trial
@en
P2093
Christopher E Walsh
Claus Banner
Eveline P Mauser-Bunschoten
Faraizah Abdul Karim
Johannes Oldenburg
Johnny Mahlangu
Karin Knobe
Pantep Angchaisuksiri
Peter W Collins
P2860
P304
P356
10.1182/BLOOD-2014-05-573055
P407
P50
P577
2014-09-26T00:00:00Z